A Selective LC Method for the Determination of Reboxetine in Human Plasma with Fluorescence Detection

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Chromatographia

• Publication date

  2007-03-21

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1365/S10337-007-0203-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A highly sensitive spectrofluorometric method for the determination of a new antidepressant drug, reboxetine, in tablets.

  2006cited by this paper
• Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service.

  2004cited by this paper
• A functional-structural model to understand cardiac autonomic nervous system (ANS) dysregulation in affective illness and to elucidate the ANS effects of antidepressive treatment.

  2004cited by this paper
• Adjunctive use of reboxetine in schizophrenia

  2004cited by this paper
• Psychiatric aspects of Parkinson’s disease

  2004cited by this paper
• A new spectrofluorimetric method for the determination of lisinopril in tablets.

  2003cited by this paper
• Determination of reboxetine, a recent antidepressant drug, in human plasma by means of two high-performance liquid chromatography methods.

  2002cited by this paper
• Bioanalysis of Racemic Reboxetine and Its Desethylated Metabolite in a Therapeutic Drug Monitoring Setting Using Solid Phase Extraction and HPLC

  2001cited by this paper
• Lack of effect of reboxetine on cardiac repolarization

  2001cited by this paper
• Effect of glucose on antipsychotic drug-induced changes in dopamine neuronal activity.

  2001cited by this paper
• Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection.

  2000cited by this paper
• Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics

  2000cited by this paper
• Reboxetine

  1999cited by this paper
• Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics.

  1999cited by this paper
• Reboxetine in the treatment of depression: Early clinical experience in the UK.

  1998cited by this paper
• Improved enantioselective method for the determination of the enantiomers of reboxetine in plasma by solid-phase extraction, chiral derivatization, and column-switching high-performance liquid chromatography with fluorescence detection.

  1998cited by this paper
• Pharmacokinetics of reboxetine enantiomers in the dog.

  1997cited by this paper
• Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding

  1995cited by this paper
• Stereoselective and species-dependent kinetics of reboxetine in mouse and rat.

  1995cited by this paper
• Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate.

  1994cited by this paper
• Haloperidol plasma levels and clinical response: a therapeutic window relationship.

  1992cited by this paper
• 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole: a new fluorigenic reagent for amino acids and other amines.

  1968cited by this paper

• Analytical Strategies for the Determination of Norepinephrine Reuptake Inhibitors in Pharmaceutical Formulations and Biological Fluids

  2016cites this paper
• Determination of reboxetine in rat brain microdialysates and plasma samples using liquid chromatography coupled to fluorescence detection.

  2012cites this paper
• The Application of 7-Chloro-4-Nitrobenzoxadiazole and 4-Fluoro-7-Nitro-2,1,3-Benzoxadiazole for The Analysis of Amines and Amino Acids Using High-Performance Liquid Chromatography

  2011cites this paper